Latest Information

  • Prometic Corporate Presentation June 2019

    Prometic Corporate Presentation June 2019

    Read PDF
  • Prometic announces share consolidation

    Prometic announces share consolidation

    Prometic is pleased to announce that the consolidation of the Corporation’s issued and outstanding common shares on the basis of one post-consolidation Common Share for every one thousand

    Read Article
  • Prometic announces voting results of its 2019 AGM

    Prometic announces voting results of its 2019 AGM

    Prometic announced the voting results from its 2019 Annual General and Special Meeting of Shareholders (“AGM”) held in Montreal, Quebec

    Read Article
  • Prometic announces completion of equity rights offering

    Prometic announces completion of equity rights offering

    Prometic is pleased to confirm the completion of its previously announced equity rights offering, raising aggregate gross proceeds of C$37,998,000 (or the equivalent of US$ 28,357,000)

    Read Article
  • Press Releases

    Read More
  • Annual Report 2018

    Annual Report 2018

    2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.

    Read PDF
  • Quarterly Report 2018 Q3

    Quarterly Report 2018 Q3

    Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.

    Read PDF
  • Quarterly Report Q2 2018

    Quarterly Report Q2 2018

    Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

    Read PDF
  • Financial Reports

    Read Now
  • Board of Directors Charter 2019

    Board of Directors Charter 2019

    Read PDF
  • Audit, Risk and Finance Committee Charter 2017

    Audit, Risk and Finance Committee Charter 2017

    The Committee is mainly responsible for the corporation's financial reporting process, process to identify & manage risks, internal & external audit process, communication systems & capital structure.

    Read PDF
  • Chairman Mandate 2018

    Chairman Mandate 2018

    The chairman of the Board of Directors of Prometic Life Sciences Inc. chairs the meetings of the Board and assures its good functioning and the good functioning of the committees of the Board.

    Read PDF
  • Virtual Tour of Prometic Life Science's Manufacturing Process6:14

    Virtual Tour of Prometic Life Science's Manufacturing Process

    You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.

    Watch Video
  • Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency2:17

    Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

    At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).

    Watch Video
  • Corporate Governance

    Read More
  • Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment1:41

    Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment

    Prometic Life Science's senior director details the promising efficacy PBI-4050 alone or in combination with nintedanib demonstrated for treatment of IPF.

    Watch Video
  • PLI Share Price

    View Now
  • loading
    Loading More...